AR114418A1 - Compuesto cíclico de metilactama y su utilización farmacéutica - Google Patents

Compuesto cíclico de metilactama y su utilización farmacéutica

Info

Publication number
AR114418A1
AR114418A1 ARP190100503A ARP190100503A AR114418A1 AR 114418 A1 AR114418 A1 AR 114418A1 AR P190100503 A ARP190100503 A AR P190100503A AR P190100503 A ARP190100503 A AR P190100503A AR 114418 A1 AR114418 A1 AR 114418A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical use
methylactam
cyclic compound
pharmaceutical
compound
Prior art date
Application number
ARP190100503A
Other languages
English (en)
Inventor
Yoshinori Tamatani
Tomoya Miura
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of AR114418A1 publication Critical patent/AR114418A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Un objetivo de la presente es el de proveer un compuesto cíclico de metilactama que presenta una actividad inhibitoria de SGLT1 y es de utilidad para un fármaco, o una sal del mismo aceptable para uso farmacéutico, una composición farmacéutica que lo comprenda, y su utilización farmacéutica. Se proporciona el siguiente compuesto de fórmula (1), o una sal aceptable para uso farmacéutico, una composición farmacéutica que lo comprenda, y su utilización farmacéutica.
ARP190100503A 2018-03-01 2019-02-28 Compuesto cíclico de metilactama y su utilización farmacéutica AR114418A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018036307 2018-03-01

Publications (1)

Publication Number Publication Date
AR114418A1 true AR114418A1 (es) 2020-09-02

Family

ID=67806229

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100503A AR114418A1 (es) 2018-03-01 2019-02-28 Compuesto cíclico de metilactama y su utilización farmacéutica

Country Status (19)

Country Link
US (2) US11014910B2 (es)
EP (1) EP3760624A4 (es)
JP (2) JP7206132B2 (es)
KR (1) KR20200128033A (es)
CN (1) CN111757877B (es)
AR (1) AR114418A1 (es)
AU (1) AU2019227770B2 (es)
BR (1) BR112020016788A2 (es)
CA (1) CA3087859A1 (es)
CL (1) CL2020002199A1 (es)
IL (1) IL276311B2 (es)
MA (1) MA52427A (es)
MX (1) MX2020009070A (es)
PE (1) PE20210123A1 (es)
PH (1) PH12020551340A1 (es)
SG (1) SG11202007120UA (es)
TW (1) TWI805699B (es)
WO (1) WO2019168096A1 (es)
ZA (1) ZA202004600B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019249560B2 (en) 2018-04-04 2023-10-05 Japan Tobacco Inc. Heteroaryl-substituted pyrazole compound and medicinal use thereof
AU2020341926A1 (en) * 2019-09-04 2022-03-17 Japan Tobacco Inc. Therapeutic or prophylactic method for diabetes using combination medicine
BR112022018396A2 (pt) 2020-03-19 2022-11-08 Japan Tobacco Inc Método de tratamento ou prevenção para insuficiência cardíaca crônica

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH04247081A (ja) 1991-02-01 1992-09-03 Takeda Chem Ind Ltd ５員複素環酸アミド類
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
KR20050096956A (ko) 2003-02-07 2005-10-06 다이이찌 세이야꾸 가부시기가이샤 피라졸 유도체
AU2004200420A1 (en) 2003-03-11 2004-09-30 Astellas Pharma Inc. Inhibitor of cyclooxygenase
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd ７員複素環誘導体
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
TW200526641A (en) 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
CA2572745A1 (en) 2004-07-07 2006-02-16 Teresa Beeson Pyrazole amide derivatives, compositions containing such compounds and methods of use
US9168278B2 (en) 2004-11-16 2015-10-27 Gw Pharma Limited Use for cannabinoid
JP2008007405A (ja) 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
JP4137956B2 (ja) * 2005-06-08 2008-08-20 日本たばこ産業株式会社 複素環化合物
CN101243074A (zh) * 2005-06-08 2008-08-13 日本烟草产业株式会社 杂环化合物
EP1889842A4 (en) 2005-06-08 2009-07-29 Japan Tobacco Inc HETEROCYCLIC CONNECTION
WO2007034279A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
JP2009523748A (ja) 2006-01-18 2009-06-25 シエナ ビオテク ソシエタ ペル アチオニ α７ニコチン性アセチルコリン受容体の調節物質およびそれらの治療への使用
EA200802132A1 (ru) * 2006-04-27 2009-06-30 Зольвай Фармасьютиклз Гмбх Фармацевтические композиции, содержащие модуляторы каннабиноидного рецептора cbи модуляторы калиевых каналов
US20080027014A1 (en) 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
CN102838532A (zh) 2006-11-24 2012-12-26 Ac免疫有限公司 用于治疗与淀粉样物质或淀粉样蛋白有关的疾病的吡唑胺和噻唑胺衍生物
US20100144793A1 (en) 2006-11-24 2010-06-10 Ac Immune Sa Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
US7838498B2 (en) * 2007-04-02 2010-11-23 Theracos, Inc. Benzylic glycoside derivatives and methods of use
US20090181952A1 (en) 2008-01-14 2009-07-16 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
KR20110028661A (ko) 2008-07-15 2011-03-21 노파르티스 아게 Ｄｇａｔ１ 억제제로서의 헤테로아릴 유도체
AU2011238616B2 (en) 2010-03-30 2016-08-04 Verseon Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
AU2019249560B2 (en) 2018-04-04 2023-10-05 Japan Tobacco Inc. Heteroaryl-substituted pyrazole compound and medicinal use thereof

Also Published As

Publication number Publication date
US20190352284A1 (en) 2019-11-21
CA3087859A1 (en) 2019-09-06
PH12020551340A1 (en) 2021-05-31
ZA202004600B (en) 2022-03-30
US20220064148A1 (en) 2022-03-03
JP7206132B2 (ja) 2023-01-17
IL276311B2 (en) 2023-10-01
AU2019227770A1 (en) 2020-07-09
WO2019168096A1 (ja) 2019-09-06
JP2023026566A (ja) 2023-02-24
JP2019151627A (ja) 2019-09-12
AU2019227770B2 (en) 2023-10-05
MX2020009070A (es) 2020-10-08
TW202000660A (zh) 2020-01-01
MA52427A (fr) 2021-01-06
KR20200128033A (ko) 2020-11-11
US11014910B2 (en) 2021-05-25
SG11202007120UA (en) 2020-08-28
EP3760624A1 (en) 2021-01-06
PE20210123A1 (es) 2021-01-19
CL2020002199A1 (es) 2020-12-18
EP3760624A4 (en) 2021-11-03
IL276311B1 (en) 2023-06-01
BR112020016788A2 (pt) 2021-01-12
CN111757877A (zh) 2020-10-09
CN111757877B (zh) 2023-10-27
TWI805699B (zh) 2023-06-21
RU2020131756A (ru) 2022-03-28
IL276311A (en) 2020-09-30

Similar Documents

Publication Publication Date Title
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
ECSP18082774A (es) Derivados aromáticos de sulfonamida
ECSP20025899A (es) Compuestos útiles para inhibir a cdk7
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
CL2019002745A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2017003032A1 (es) Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
CL2019002744A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
ECSP20035590A (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
BR112015030399B8 (pt) Derivados heterocíclicos, uso dos referidos derivados e composição farmacêutica para a prevenção ou tratamento de doenças associadas com a ativação da proteína stat3
AR114418A1 (es) Compuesto cíclico de metilactama y su utilización farmacéutica
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
WO2016068580A3 (en) Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
CL2021002480A1 (es) Agonistas compuestos macrocíclicos como de sting
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
BR112021023927A2 (pt) Composto, e, composição farmacêutica
AR095032A1 (es) Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo
BR112017015744A2 (pt) composto apresentando uma estrutura de fórmula (i), um sal farmaceuticamente aceitável do mesmo ou um isômero ótico do mesmo, composição farmacêutica e uso do composto de fórmula (i) para o tratamento e prevenção de mycobacterium tuberculosis ou outras infecções microbianas
CL2017002229A1 (es) Inhibidores de bace1.
CL2020000251A1 (es) Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico.
AR083780A1 (es) Composicion farmaceutica para tratar infecciones del hcv